A six-month, double-blind, placebo-controlled, single-site study of Cerefolin NAC on blood homocysteine, oxidative stress, and beta-amyloid biomarkers that may potentiate inflammation and neuronal damage in older individuals with memory complaints who have not been clinically diagnosed with mild cognitive impairment, vascular dementia, or Alzheimer’s disease

The goal of this double-blind study is to determine if Cerefolin NAC reduces blood markers associated with inflammation and oxidative stress more than a standard multivitamin in older persons with memory concerns.   Reducing inflammation and oxidative stress blood markers may enable brain cells to function better and survive longer.

The study is being conducted only by the Rush Alzheimer’s Disease Center. It is sponsored and funded by Pamlab, LLC.

Duration of the study is seven months with four evaluation visits. Eligible participants will receive Cerefolin NAC or placebo to take daily. All participants will receive a standard multivitamin to take daily.

Each evaluation visit will be a combination of all or some of the following: testing of memory, walking ability, mood, and function; neurological exams; and blood draws.

There will be no cost to participants who volunteer for the study. The study drug and all visits will be covered by the research study.

You may be eligible to participate in this study if you:

• Are between 60 years of age or older
• Have memory complaints
• Are willing to replace current vitamin with a standardized multivitamin for the duration of the study

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.